The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma

The Revised International Staging System (R-ISS) stratifies patients affected by Multiple Myeloma (MM) into three distinct risk groups: R-ISS I [ISS Stage I, Standard-Risk cytogenetics and normal Lactase DeHydrogenase (LDH)], III (ISS stage either high-risk or high LDH) II (any other characteristics). With the aim to verify whether groups could be divided subgroups with different prognostic factors based on detection of Circulating Plasma Cells (CPCs) at diagnosis, in this retrospective analysis, we evaluated 161 MM treated our centre between 2005 2017. In all, 57 (33·9%) were staged as III, 98 (58·3%) six (3·6%) I. CPCs detected 125 (74·4%), while 43 (25·6%) no seen. Our analysis revealed that Overall Survival (OS) progression-free survival (PFS) rates higher subgroup without compared ≥1 (OS: 44·7% vs. 16·3%, P = 0·0089; PFS: 27·8% 8·1%, 0·0118). present findings suggest diagnosis may used a further biomarker improve stratification II.